

In Situ Hybridization: Market Strategies and Forecasts, US, 2018-2024

Table of Contents

In Situ Hybridization: Executive Summary

The study is designed to give a comprehensive overview of the In Situ Hybridization market segment. Research represents a selection from the mountains of data available of the most relevant and cogent market materials, with selections made by the most senior analysts. Commentary on every aspect of the market from independent analysts creates an independent perspective in the evaluation of the market. In this manner the study presents a comprehensive overview of what is going on in this market, assisting managers with designing market strategies likely to succeed.

Table of Contents

Abstract: In Situ Hybridization Reagents Make It Possible To Visualize Expression Of Virtually Any Gene In Individual Cells While Retaining Valuable Tissue Morphology Information	1
Table of Contents	3
US In situ Hybridization Executive Summary	15
In Situ Hybridization (ISH)	15
1. United States In Situ Hybridization ISH Market Definition and Market Dynamics	16
1.1 US In situ Hybridization Market Overview	16
1.1.1 Antibody Challenges and Validation	16
1.2 Scope of In situ Hybridization in Inflammation	17
1.2.1 RNAscope® Applications	17
2. In-Situ Hybridization Market Shares and Market Forecasts	20
2.1 In-Situ Hybridization Market Driving Forces	20
2.1.1 Identification of Cytokines and their Cellular Origins	21

2.1.2	Detection of Long Non-Coding RNA (lncRNA) in Inflammatory Diseases	21
2.1.3	Role of Inflammatory Pathways During Carcinogenesis	22
2.1.4	Therapeutic Potential Of Secreted Proteins In Inflammatory Diseases	22
2.1.5	Dual ISH-IHC Detect Cytokines During Inflammatory Responses	22
2.2	In Situ Hybridization Market Shares	24
2.2.1	Roche	25
2.2.2	Abbott Molecular	25
2.2.3	Advanced Cell Diagnostics	25
2.2.4	PerkinElmer In Situ Hybridization Market Driving Forces	26
2.2.5	In Situ Hybridization Market Shares, Unit Shipments and Kit Shipments	27
2.3	In Situ Hybridization Market Forecasts	29
2.3.5	In Situ Hybridization Market Segments, Units and Kits, Dollars and Percent, US,	29
2.4	In situ Hybridization Market Segments	31
2.4.1	In Situ Hybridization Market Shares, Dollars, Worldwide, 2012 to 2017	32
2.4.2	Fluorescence (FISH) and Chromogenic (CISH) Detection	33
2.4.3	ISH Applications	36
2.4.4	Multiplex Fluorescence In Situ Hybridization (FISH)	36
2.4.5	Fluorescence In Situ Hybridization (FISH)	37
2.4.6	Cancer Drug Market	40
2.4.7	Chronic Lymphocytic Leukemia (CLL)	40
2.4.8	In-Situ Hybridization Cancer Diagnosis, Cytology, Infectious Disease	
	Molecular Diagnostic	42

2.1.6 In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies	47
2.5 In-Situ Hybridization Pricing	54
2.5.1 miRCURY LNA miRNA Detection Probes	54
2.5.2 Price and Availability	58
2.6 In-Situ Hybridization Geographical Analysis	61
3 In-Situ Hybridization Research and Technology	68
3.1 Hybridization Technique	68
4 In-Situ Hybridization Company Profiles	69
4.1 Abbott Laboratories	69
4.1.1 Abbott Laboratories Market Categorization	69
4.1.2 In Situ Hybridization Product Category, Application and Specification	70
4.1.3 Abbott Laboratories Vysis Chronic Lymphocytic Leukemia (CLL) FISH Probe Kit (IVD)	71
4.1.4 Vysis CLL FISH Probe Kit Contents	72
4.1.5 Acupath Laboratories Test For Detecting Bladder Cancer Uses Probes from Abbott Molecular	74
4.1.6 Abbott Laboratories Barrett’s Esophagus FISH	75
4.1.7 Abbott Molecular Vysis CLL FISH Probe Kit	77
4.1.8 Abbott Laboratories Revenue	77
4.1.9 Abbott Laboratories ThermoBrite System	81
4.1.10 Abbott Laboratories User Programmable Settings	82
4.1.11 Abbott Laboratories Vysis FISH Chromosome Search	83
4.1.12 Abbott Laboratories Molecular Diagnostics	84
4.1.13 Abbott Diagnostic Products	85
4.2 Acupath Laboratories	87

4.2.1	Acupath Laboratories Barrett’s Esophagus FISH	88
4.3	Agilent Technologies	88
4.3.1	Agilent CGH & CGH+SNP Microarrays	91
4.3.2	Agilent Technologies Revenue	91
4.3.3	Agilent Diagnostics and Genomics	93
4.4	Bio-Techne / ACD	96
4.4.1	Bio-Techne ACD RNAscope Widely Used In-Situ Hybridization Technique	97
4.4.2	Bio-Techne Revenue	98
4.4.3	Biotechne US Regional Analysis	101
4.4.4	Advanced Cell Diagnostics	102
4.5	F. Hoffmann-La Roche AG	102
4.5.1	Roche Gene Amplification by Fluorescence In Situ Hybridization	104
4.5.2	Roche Automated RNA isolation	105
4.5.3	Roche Fluorescence In Situ Hybridization (FISH)	105
4.5.4	Roche Agreement with Merck Millipore Sigma	106
4.5.5	Roche Immuno Diagnostics	108
4.5.6	F. Hoffmann-La Roche AG Revenue	109
4.5.7	Roche Buys Flatiron Health Leader In Oncology-Specific Electronic Health Record (EHR) Software	114
4.6	Danaher / Leica Biosystems Nussloch GmbH	115
4.6.1	Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments	116
4.6.2	Leica Biosystems Nussloch GmbH Revenue	122
4.6.3	Danaher Geographical Revenue	124
4.7	Thermo Fisher Scientific	125
4.7.1	Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH)	125
4.7.2	Chromogenic In Situ Hybridization (CISH)	128

4.7.3	Thermo Fisher Scientific Revenue	133
4.8	Merck KGaA	134
4.9	PerkinElmer	135
4.9.1	PerkinElmer Stain	144
4.9.2	Perkin Elmer Revenue	146
4.10	Qiagen / Exiqon A/S	150
4.10.1	Qiagen’s GeneReader NGS System	153
4.10.2	Polygenetic Mutations Drive Cancer	153
4.10.3	Qiagen Revenue	154
4.11	BioGenex Laboratories	155
4.11.1	BioGenex Fully-Automated Molecular Pathology Workstation	156
4.11.2	BioGenex Boosts Genome Research and Diagnostics - BioGenex US	159
4.11.3	BioGenex Antibodies for Cancer Diagnosis	161
4.11.4	BioGenex PMS2	161
CK5		162
4.11.5	eFISHiency System for the Analysis of Solid Tumors - BioGenex US	163
4.12	Bio SB	165
4.12.1	Bio SB Zytovision Molecular Diagnostics	165
4.13	Bio-Techne / Advanced Cell Diagnostics (ACD)	167
5	Summary and Conclusions	172
5.1	Analyze A Marker At The Single Cell Level	172
5.2	Advances in RNA In Situ Hybridization	172
6	Appendix A: List Of Nucleic Acid-Based Tests	173
6.1	List: Nucleic Acid-Based Tests Approved by US Center for Devices and Radiological Health	173
6.1.1	List of Human Genetic Tests	174
6.1.2	List of Microbial Tests	191
6.2	In Vitro Diagnostics	233

WinterGreen Research,	235
WinterGreen Research Methodology	236
WinterGreen Research Process	237
Market Research Study	238
WinterGreen Research Global Market Intelligence Company	239

Abstract: In Situ Hybridization Reagents Make It Possible To Visualize Expression Of Virtually Any Gene In Individual Cells While Retaining Valuable Tissue Morphology Information	1
--	---

Figure 1. In Situ Hybridization Market Shares, Dollars, US, 2016 and 2017	24
---	----

Figure 2. In Situ Hybridization Market Driving Forces	26
---	----

Figure 3. In Situ Hybridization Market Shares, Unit Shipments and Kit Shipments, Units and Dollars, US, 2017	27
--	----

Figure 4. In Situ Hybridization Market Shares, \$ per Unit and \$ per Kit, Dollars and Percent, US, 2017	28
--	----

Figure 5. In Situ Hybridization Market Segments, Unit Shipments and Kit Shipments, Units and Dollars, US, 2017	29
--	----

Figure 6. In Situ Hybridization Market Segments, \$ per Unit and \$ per Kit, Dollars and Percent, US, 2017	30
--	----

Figure 7. In Situ Hybridization Market Shares, Dollars, Worldwide, 2012 to 2017	32
---	----

Figure 8. In Situ Hybridization Market Segments, Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), US, 2012 to 2017	33
---	----

Figure 9. In Situ Hybridization Market Segments, Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), US, 2017 to 2024	34
---	----

Figure 10. Thermo Fisher Scientific Characteristics of In Situ Hybridization Methods	35
--	----

Figure 11. Diagnostics Growth	42
-------------------------------	----

Figure 12. In Situ Hybridization Market Segments, Cancer, Chromosomal Abnormalities, Infectious Diseases, Dollars, US, 2012 to 2017	43
Figure 13. In Situ Hybridization Market Segments, Cancer, Chromosomal Abnormalities, Infectious Diseases, Dollars, US, 2017 to 2024	44
Figure 14. In Situ Hybridization Market Segments, Cancer, Chromosomal Abnormalities, Infectious Diseases, Percent, US, 2017 to 2024	45
Figure 15. In Situ Hybridization Market Segments, Cancer, Chromosomal Abnormalities, Infectious Diseases, Percent, US, 2012 to 2017	45
Figure 16. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Dollars, US, 2012 to 2017	47
Figure 17. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Dollars, US, 2017 to 2024	48
Figure 18. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Percent, US, 2012 to 2017	49
Figure 19. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Percent, US, 2017 to 2024	50
Figure 20. 575 Million People with Autoimmune Disease	51
Figure 21. PerkinElmer Assays for Autoimmune Disease	52
Figure 22. PerkinElmer Diagnostics	53
Figure 23. PerkinElmer In Situ Hybridization	57
Figure 24. In Situ Hybridization Regional Analysis, US: West, Rocky Mountain, Southwest, Midwest, South, Middle Atlantic, New York and New England, Percent, 2012 – 2017	63
Figure 25. In Situ Hybridization Regional Analysis, US: West, Rocky Mountain, Southwest, Midwest, South, Middle Atlantic, New York and New England, Percent, 2017 - 2024	65
Figure 26. Abbott Laboratories Vysis CLL FISH Probe Kit Probe Info	71
Figure 27. Abbott Laboratories Vysis CLL FISH Probe Kit Contents	72
Figure 28. Abbott Laboratories Vysis CLL FISH Probe Kit includes LSI	72

Figure 29. Abbott Vysis CLL FISH Probe Kit	73
Figure 30. Abbott Laboratories Segment Sales, 2017	78
Figure 31. Abbott Segment Sales 2015-2017	79
Figure 32. Abbott Geographical Revenue	80
Figure 33. Abbott Laboratories ThermoBrite System	81
Figure 34. Abbott Laboratories ThermoBrite System Functions	82
Figure 35. Abbott Laboratories Molecular Testing	84
Figure 36. Abbott Diagnostic Product Target Markets	85
Figure 37. Abbott Diagnostic Principal Products	86
Figure 38. In Situ Hybridization Detection System: Agilent Product Area: Standard Nucleic Acid Detection System	88
Figure 39. PNA ISH Detection Kit Product Area: PNA Probes & Detection System	90
Figure 40. Roche RNA Isolation Kit	105
Figure 41. Merck MilliporeSigma and Sigma-Aldrich and Roche Offerings	107
Figure 42. Key points of the Roche Merc agreement include:	107
Figure 43. Roche Immuno Diagnostics DISCOVERY XT	108
Figure 44. Roche DISCOVERY XT Research Instrument Functions	109
Figure 45. F. Hoffmann-La Roche AG Sales	110
Figure 46. Roche by the Metrics	112
Figure 47. F. Hoffmann-La Roche AG Pharmaceutical Sales	113
Figure 48. Danaher Brands	116
Figure 49. Leica Biosystems Bond III Technical Specifications	117
Figure 50. Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments	118
Figure 51. Leica SCN400 Slide Scanner Features	119
Figure 52. Leica BOND Ready-To-Use Antibodies (No Mixing, Titration Or Dilution)	120
Figure 53. Leica Biosystems	121
Figure 54. Danaher Segment Revenue	123

Figure 55. Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) Positioning	125
Figure 56. Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) In Situ Hybridization (ISH) Technologies	126
Figure 57. Thermo Fisher Scientific Characteristics of In Situ Hybridization Methods	127
Figure 58. 5.7.1 Thermo Fisher Scientific EVOS Cell Imaging Systems	129
Figure 59. Thermo Fisher Scientific Fluorescence Systems	130
Figure 60. Thermo Fisher Scientific Cell Analysis	131
Figure 61. Thermo Fisher Scientific Imaging Portfolio Components	132
Figure 62. Thermo Fisher Scientific Revenue	133
Figure 63. PerkinElmer In Situ Hybridization	136
Figure 64. PerkinElmer In Situ Hybridization	137
Figure 65. PerkinElmer In Situ Hybridization	139
Figure 66. PerkinElmer Financials at a Glance	140
Figure 67. PerkinElmer Diagnostics Revenue	141
Figure 68. PerkinElmer in situ hybridization Expanding Diagnostics Market Reach and Global Impact	142
Figure 69. PerkinElmer Diagnostics	143
Figure 70. PerkinElmer Stain	144
Figure 71. Perkin Elmer Revenue	146
Figure 72. PerkinElmer offers Ultra-Sensitive And Specific Mirna Detection By In Situ Hybridization (ISH) Functions	149
Figure 73. miRCURY LNA miRNA Detection Probes	151
Figure 74. BioGenex Performance Systems	156
Figure 75. BioGenex Product Areas	157
Figure 76. BioGenex Performance Systems / BioGenex Flagship Products	157
Figure 77. BioGenex Customers	158

Figure 78. Figure: Colon Carcinoma stained with PMS2 (clone EP51), Staining in FFPE tissues, using DAB chromogen and BioGenex Polymer-HRP Detection System.	162
Figure 79. BioGenex Cervical Cancer Stained with Anti-Human CK-5 (clone EP24), Staining in FFPE Tissues, Using DAB Chromogen and Polymer-HRP Detection System	163
Figure 80. BioGenex Fish Steps Reduction	164
Figure 81. BioGenex eFISHiency System Reduces Hands-On Processing Time To 30 Minutes	165
Figure 82. Bio SB Zytovision Molecular Diagnostics	165
Figure 83. Bio-Techne / ACD	170

www.wintergreenresearch.com

(781) 863-5078